Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 4 1Phase 3 1Phase 1/2 1Phase 1 1

Status

Completed 30Terminated 13Unknown 6Active not recruiting 6Withdrawn 4Recruiting 4Not yet recruiting 1No longer available 1

Sponsor Class

OTHER 4OTHER_GOV 1INDUSTRY 1

Study Type

Interventional 6

Sponsor

Cancer Type

Lymphoid 3Plasma cell 2Other hematologic neoplasm 1CNS 1

Conditions

Multiple Myeloma 37Neoplasms, Plasma Cell 11Recurrence 6Lymphoma, Mantle-Cell 4Precursor Cell Lymphoblastic Leukemia-Lymphoma 2Peripheral Nervous System Diseases 2Lymphoma, Large B-Cell, Diffuse 2Leukemia, Myeloid, Acute 2Immunoglobulin Light-chain Amyloidosis 2Glioblastoma 2Waldenstrom Macroglobulinemia 1Renal Insufficiency 1Rectal Neoplasms 1Pathologic Complete Response 1Paraproteinemias 1Pancreatic Neoplasms 1Ovarian Neoplasm Epithelial 1Neoplasms by Histologic Type 1Neoplasms 1Neoplasm, Residual 1Mesothelioma, Malignant 1Mesothelioma 1Lymphoma, T-Cell, Peripheral 1Lymphoma, B-Cell, Marginal Zone 1Lymphoma 1Liver Neoplasms 1Leukemia, Promyelocytic, Acute 1Leukemia, Plasma Cell 1Leukemia 1Hypoxia 1

Interventions

Cyclophosphamide 17fludarabine 13Dexamethasone 12Cisplatin 12Rituximab 10Gemcitabine 9Paclitaxel 8Bendamustine Hydrochloride 8Lenalidomide 7Decitabine 7Cytarabine 7Carboplatin 7fludarabine phosphate 6N-(2-amino-5-fluorobenzyl)-4-(N-(pyridine-3-acrylyl)aminomethyl)benzamide 6Etoposide 6Bortezomib 6Radiotherapy 5Injections 5Azacitidine 5camrelizumab 4apatinib 4Valproic Acid 4Thalidomide 4Procarbazine 4Oxaliplatin 4Drug Therapy 4Bevacizumab 4Antilymphocyte Serum 4venetoclax 3pomalidomide 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

6 trials
RecentStart dateEnrollment
Unknown × Recurrence × Bortezomib × Clear all
NCT03643549 2024-02-29

BORTEM-17

Haukeland University Hospital

Phase 1/2 Unknown
63 enrolled
CNS

Glioblastoma, Recurrence

NCT05052970 2022-02-01

Mitoxantrone Hydrochloride Liposome Injection, Bortezomib and Dexamethasone in the Treatment of R/R MM

CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd.

Phase 1 Unknown
60 enrolled
Plasma cell

Multiple Myeloma, Recurrence

NCT05137860 2022-01-18

Efficacy of the Use of Bortezomib for the Treatment of Relapsed Leukemia or Positive MRD

Hospital General de Mexico

Phase 4 Unknown
56 enrolled
LymphoidOther hematologic neoplasm

Recurrence, Neoplasm, Residual, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT01449344 2017-03-07

(R-HAD)

European Mantle Cell Lymphoma Network

Phase 3 Unknown
128 enrolled
Lymphoid

Recurrence, Lymphoma, Mantle-Cell

NCT00508209 2010-06-22

Bortezomib and High-dose Melphalan at Myeloma Relapse

Nordic Myeloma Study Group

Phase 2 Unknown
50 enrolled
Plasma cell

Multiple Myeloma, Recurrence

NCT00261612 2006-10-18

Bortezomib, Rituximab and Dexamethasone (BORID) for Relapsed/Refractory Mantle Cell Lymphoma

Medical University of Vienna

Phase 2 Unknown
16 enrolled
Lymphoid

Recurrence, Lymphoma, Mantle-Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡